Preliminary lab tests found BioHarvest's olive ingredient reduced collagen buildup in liver cells by up to 50%.
BioHarvest Sciences announced its proprietary Olive Cell composition, derived from olive fruit, has reached commercial readiness. The company completed development, manufacturing, and GRAS process for the asset, which showed promising preclinical activity in liver health models. BioHarvest plans to license and commercialize Olive Cell through its CDMO business, marking its second proprietary plant-cell-derived composition after VINIA.
How this was made
The 30-second read
Why it matters
The release signals a new revenue stream potential but lacks concrete deal terms, making the immediate market impact uncertain.
Market read
First disclosure of a commercial‑scale, GRAS‑cleared biotech ingredient; may attract CDMO customers and investors seeking exposure to novel nutraceutical platforms.
What to watch
Regulatory timelines for GRAS claims and competition from traditional olive extracts could temper upside.
Background
BioHarvest Sciences (NASDAQ: BHST) uses its Botanical Synthesis™ platform to produce plant‑cell derived ingredients. The Olive Cell product is the second asset to reach commercial readiness after VINIA®.
Ticker impact
BioHarvest announced its Olive Cell ingredient is manufacturing‑ready and available for licensing, marking the first public disclosure of a commercial‑scale, GRAS‑cleared product.
potential upward pressure as investors price in future licensing revenue
No immediate revenue disclosed; market reaction will hinge on partner announcements and royalty expectations.
Market effects
Highlights progress in plant‑cell biotech and could spur interest in similar CDMO platforms.
May benefit Canadian biotech sector where BioHarvest is headquartered.
Limited; relevance confined to niche nutraceutical and cosmetic ingredient markets.
Counterpoint
Without signed licensing deals, the news may be overhyped and could lead to short‑term disappointment.
Key entities
- companyBioHarvest Sciences Inc.
Biotech firm developing plant‑cell derived ingredients.
- productOlive Cell
Proprietary olive‑derived Verbascoside composition ready for licensing.
